Cetuximab-associated skin ulceration in patient with metastatic colorectal cancer - A case report

Japanese Journal of Cancer and Chemotherapy

Volumn 38, Issue 9, 2011, Pages 1549-1552

  Tsuboi, Kenji ^a   Kawase, Yoshihisa ^a   Okochi, Osamu ^a   Hattori, Masashi ^a   Takami, Yuko ^a   Takeda, Shigeomi ^a   Mizuno, Akira ^a   Sato, Yusuke ^a   Uno, Yasuo ^a   Hayashi, Takao ^a   Sasada, Yoshie ^a   Takamura, Shinobu ^a   Kozaki, Koji ^a  

^a TOSEI GENERAL HOSPITAL   (Japan)

Author keywords

Cetuximab; Metastatic colorectal cancer; Skin ulcer

Indexed keywords

BEVACIZUMAB; CETUXIMAB; TEGAFUR;

AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CLASSIFICATION; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CASE REPORT; COLORECTAL CANCER; CONTINENCE; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HUMAN; LUNG METASTASIS; LYMPH NODE METASTASIS; MULTIPLE CYCLE TREATMENT; PARAAORTIC LYMPH NODE; POSTOPERATIVE CARE; SKIN ULCER; STOMA; TREATMENT DURATION; ULCER HEALING;

EID: 81855212523     PISSN: 03850684     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (7)

1. Tournigand C, André T, Achille E, et al.: FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer a randomized GERCOR study. J Clin Oncol 12(2): 229-237, 2004. (Pubitemid 41095086)
2. Cunningham D, Atkin W, Lenz HJ, et al.: Colorectal cancer. Lancet 375(9719): 1030-1047, 2010.
3. Kabbinavar F and Shah A: Guidelines for the management of side effects of bevacizumab in patients with colorectal cancer. Cancer Ther 6: 327-339, 2008.
4. Segaert S and Van Cutsem E: Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol 16(9): 1425-1433, 2005. (Pubitemid 41222414)
5. Harari PM and Huang SM: Searching for Reliable Epidermal Growth Factor Receptor Response Predictors. Clin Cancer Res 10(2): 428-432, 2004. (Pubitemid 38173978)
6. Mascia F, Mariani V, Girolomoni G, et at Blockade of the EGF receptor induces a deranged chemokine expression in keratinocytes leading to enhanced skin inflammation. Am J Pathol 163(1): 303-312, 2003.
7. Pryor DI, Porceddu SV, Burmeister BH, et at Enhanced toxicity with concurrent cetuximab and radiotherapy in head and neck cancer. Radiother Oncol 90(2): 172-176, 2009.